These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21813328)

  • 1. Effects of a food supplement rich in arginine in patients with smear positive pulmonary tuberculosis--a randomised trial.
    Schön T; Idh J; Westman A; Elias D; Abate E; Diro E; Moges F; Kassu A; Ayele B; Forslund T; Getachew A; Britton S; Stendahl O; Sundqvist T
    Tuberculosis (Edinb); 2011 Sep; 91(5):370-7. PubMed ID: 21813328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide production in the exhaled air of patients with pulmonary tuberculosis in relation to HIV co-infection.
    Idh J; Westman A; Elias D; Moges F; Getachew A; Gelaw A; Sundqvist T; Forslund T; Alemu A; Ayele B; Diro E; Melese E; Wondmikun Y; Britton S; Stendahl O; Schön T
    BMC Infect Dis; 2008 Oct; 8():146. PubMed ID: 18950489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of micronutrient supplementation on treatment outcome in patients with pulmonary tuberculosis: a randomized controlled trial in Mwanza, Tanzania.
    Range N; Andersen AB; Magnussen P; Mugomela A; Friis H
    Trop Med Int Health; 2005 Sep; 10(9):826-32. PubMed ID: 16135188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of sedimentation rate, viral load and TNF-alpha in relation to HIV co-infection in tuberculosis.
    Schön T; Wolday D; Elias D; Melese E; Moges F; Tessema T; Stendahl O; Sundqvist T; Britton S
    Trans R Soc Trop Med Hyg; 2006 May; 100(5):483-8. PubMed ID: 16242741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of energy-protein supplementation on weight, body composition and handgrip strength among pulmonary tuberculosis HIV-co-infected patients: randomised controlled trial in Mwanza, Tanzania.
    PrayGod G; Range N; Faurholt-Jepsen D; Jeremiah K; Faurholt-Jepsen M; Aabye MG; Jensen L; Jensen AV; Grewal HM; Magnussen P; Changalucha J; Andersen AB; Friis H
    Br J Nutr; 2012 Jan; 107(2):263-71. PubMed ID: 21729372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coinfection and clinical manifestations of tuberculosis in human immunodeficiency virus-infected and -uninfected adults at a teaching hospital, northwest Ethiopia.
    Kassu A; Mengistu G; Ayele B; Diro E; Mekonnen F; Ketema D; Moges F; Mesfin T; Getachew A; Ergicho B; Elias D; Aseffa A; Wondmikun Y; Ota F
    J Microbiol Immunol Infect; 2007 Apr; 40(2):116-22. PubMed ID: 17446959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis.
    Schön T; Elias D; Moges F; Melese E; Tessema T; Stendahl O; Britton S; Sundqvist T
    Eur Respir J; 2003 Mar; 21(3):483-8. PubMed ID: 12662006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia.
    Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn PP
    J Trop Med Hyg; 1995 Feb; 98(1):9-21. PubMed ID: 7861484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical aspects and treatment outcome in HIV-associated pulmonary tuberculosis: an experience from a Thai referral centre.
    Hongthiamthong P; Riantawan P; Subhannachart P; Fuangtong P
    J Med Assoc Thai; 1994 Oct; 77(10):520-5. PubMed ID: 7745373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of anti-tuberculosis treatment among patients receiving highly active antiretroviral therapy at Vihiga district hospital in 2007.
    Kwange SO; Budambula NL
    Indian J Med Microbiol; 2010; 28(1):21-5. PubMed ID: 20061758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sputum smear conversion during intensive TB treatment phase according to HIV status, in hospitalised patients in Togo].
    Wateba MI; Diop SA; Salou M; Womitso K; Nichols S; Tidjani O
    Med Mal Infect; 2011 Mar; 41(3):140-4. PubMed ID: 21282024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality rates and recurrent rates of tuberculosis in patients with smear-negative pulmonary tuberculosis and tuberculous pleural effusion who have completed treatment.
    Banda H; Kang'ombe C; Harries AD; Nyangulu DS; Whitty CJ; Wirima JJ; Salaniponi FM; Maher D; Nunn P
    Int J Tuberc Lung Dis; 2000 Oct; 4(10):968-74. PubMed ID: 11055765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment results of DOTS in 1797 Sudanese tuberculosis patients with or without HIV co-infection.
    El-Sony AI; Khamis AH; Enarson DA; Baraka O; Mustafa SA; Bjune G
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1058-66. PubMed ID: 12546113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Smear-negative' pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence.
    Hargreaves NJ; Kadzakumanja O; Whitty CJ; Salaniponi FM; Harries AD; Squire SB
    Int J Tuberc Lung Dis; 2001 Sep; 5(9):847-54. PubMed ID: 11573897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of pulmonary tuberculosis suspects with negative sputum smears and normal or minimally abnormal chest radiographs in resource-poor settings.
    Harries AD; Banda HT; Boeree MJ; Welby S; Wirima JJ; Subramanyam VR; Maher D; Nunn P
    Int J Tuberc Lung Dis; 1998 Dec; 2(12):999-1004. PubMed ID: 9869116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled, 1:1 randomized Phase III clinical trial of Immunoxel honey lozenges as an adjunct immunotherapy in 269 patients with pulmonary tuberculosis.
    Batbold U; Butov DO; Kutsyna GA; Damdinpurev N; Grinishina EA; Mijiddorj O; Kovolev ME; Baasanjav K; Butova TS; Sandagdorj M; Batbold O; Tseveendorj A; Chunt E; Zaitzeva SI; Stepanenko HL; Makeeva NI; Mospan IV; Pylypchuk VS; Rowe JL; Nyasulu P; Jirathitikal V; Bain AI; Tarakanovskaya MG; Bourinbaiar AS
    Immunotherapy; 2017 Jan; 9(1):13-24. PubMed ID: 27868466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of drug susceptibility pattern and mycobacterial species in sputum smear positive pulmonary tuberculosis patients with and without HIV co-infection in north west Ethiopia.
    Mekonen M; Abate E; Aseffa A; Anagaw B; Elias D; Hailu E; Idh J; Moges F; Wolde-Amanuel Y; Asrat D; Yamuah L; Britton S; Stendahl O; Schön T
    Ethiop Med J; 2010 Jul; 48(3):203-10. PubMed ID: 21073081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients.
    Hesseling AC; Walzl G; Enarson DA; Carroll NM; Duncan K; Lukey PT; Lombard C; Donald PR; Lawrence KA; Gie RP; van Helden PD; Beyers N
    Int J Tuberc Lung Dis; 2010 May; 14(5):560-70. PubMed ID: 20392348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.